Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): A case/non-case study from the French Pharmacovigilance Database

European Journal of Clinical Pharmacology

Volumn 60, Issue 9, 2004, Pages 673-677

  Lugardon, S ^a   Lapeyre Mestre, M ^a   Montastruc, J L ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; GLUCOCORTICOID; IBUPROFEN; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PIROXICAM; ROFECOXIB;

ARTICLE; CASE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; DUODENITIS; DUODENUM ULCER; ESOPHAGITIS; ESOPHAGUS ULCER; GASTRITIS; GASTROINTESTINAL SYMPTOM; HUMAN; PRIORITY JOURNAL; STOMACH ULCER; UPPER GASTROINTESTINAL TRACT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DATABASES, FACTUAL; DUODENITIS; ESOPHAGITIS; FEMALE; FRANCE; GASTRITIS; GASTROINTESTINAL DISEASES; HUMANS; LACTONES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RETROSPECTIVE STUDIES; SULFONAMIDES; SULFONES; ULCER; UPPER GASTROINTESTINAL TRACT;

EID: 11244327725     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0813-5     Document Type: Article

References (26)

1. Montastruc JL (2003) Pharmacology: selective for whom? Marketing ploy. Prescrire Int 12:119
2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, VIGOR Study group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520-1528
3. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247-1255
4. Layton D, Riley J, Wilton LV, Shakir SA (2003) Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study. Br J Clin Pharmacol 55:166-174
5. WHO (2000) Celecoxib: adverse reaction reports. WHO Drug Inf 14:93-94
6. Egberts AC, Meyboom RH, De Koning FH, Bakker A, Leufkens HG (1997) Non-puerperal lactation associated with antidepressant drug use. Br J Clin Pharmacol 44:277-281
7. Moore N, Kreft-Jais C, Haramburu F, Noblet C, Andrejak M, Ollagnier M, Begaud B (1998) Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 44:513-518
8. Egberts AC, Meyboom RH, van Puijenbroek EP (2002) Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf 25:453-458
9. Stricker BH, Tijssen JG (1992) Serum sickness-like reactions to cefaclor. J Clin Epidemiol 45:1177-1184
10. Moore N, Noblet C, Kreft-Jais C, Lagier G, Ollagnier M, Imbs JL (1995) French pharmacovigilance database system: examples of utilisation. Therapie 50:557-562
11. WHO (1992) International monitoring of adverse reactions to drugs: adverse reaction terminology. WHO collaborating Centre for International Drug Monitoring, Uppsala
12. Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255-1259
13. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ (1999) Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 282:1929-1933
14. Begaud B, Evreux JC, Jouglard J, Lagier G (1985) Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 40:111-118
15. MacDonald TM, Morant SV, Goldstein JL, Burke TA, Pettitt D (2003) Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 52:1265-1270
16. Van der Heijden PG, van Puijenbroek EP, van Buuren S, van der Hofstede JW (2002) On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Stat Med 21:2027-2044
17. Desboeuf K, Lapeyre-Mestre M, Montastruc JL (1998) Risk of gastrointestinal haemorrhage with calcium antagonists. Br J Clin Pharmacol 46:87-89
18. Wilson AM, Thabane L, Holbrook A (2004) Application of data mining data in pharmacovigilance. Br J Clin Pharmacol 57:127-134
19. Henry D, Dobson A, Turner C (1993) Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 105:1078-1088
20. Garcia-Rodriguez L, Hernandez-Diaz S (2001) Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 12:570-576
21. Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G, Austin J, Laupacis A (2002) Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 325:624
22. Laporte JR, Ibanez L, Vidal X, Vendrell L, Leone R (2004) Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 27:411-420
23. Mamdani M, Juurlink DN, Kopp A, Naglie G, Austin PC, Laupacis A (2004) Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ 328:1415-1416
24. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O' Neill GP, Quellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I et al (1999) Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290:551-560
25. Laporte JR, Carne X, Vidal X, Moreno V, Juan J (1991) Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding. Lancet 337:85-89
26. Garcia Rodriguez LA, Jick H (1994) Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343:769-772